X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ACTAVIS (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   ACTAVIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ACTAVIS
Dec-14
SANOFI INDIA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs4,56017,418-   
Low Rs4,40010,625-   
Sales per share (Unadj.) Rs1,028.53,136.6-  
Earnings per share (Unadj.) Rs129.0-391.4-  
Cash flow per share (Unadj.) Rs186.0287.8-  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.66,803.1-  
Shares outstanding (eoy) m23.03265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.5 97.4%   
Avg P/E ratio x34.7-35.8 -97.0%  
P/CF ratio (eoy) x24.148.7 49.4%  
Price / Book Value ratio x5.92.1 288.4%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1743,728,306 2.8%   
No. of employees `0003.621.6 16.8%   
Total wages/salary Rs m3,5920-   
Avg. sales/employee Rs Th6,537.738,611.5 16.9%   
Avg. wages/employee Rs Th991.40-   
Avg. net profit/employee Rs Th819.8-4,818.3 -17.0%   
INCOME DATA
Net Sales Rs m23,686834,009 2.8%  
Other income Rs m708-2,082 -34.0%   
Total revenues Rs m24,394831,927 2.9%   
Gross profit Rs m5,281107,140 4.9%  
Depreciation Rs m1,313180,593 0.7%   
Interest Rs m1526,306 0.1%   
Profit before tax Rs m4,661-101,841 -4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,470 0.0%   
Tax Rs m1,691-5,236 -32.3%   
Profit after tax Rs m2,970-104,076 -2.9%  
Gross profit margin %22.312.8 173.6%  
Effective tax rate %36.35.1 705.7%   
Net profit margin %12.5-12.5 -100.5%  
BALANCE SHEET DATA
Current assets Rs m15,673439,416 3.6%   
Current liabilities Rs m6,678320,463 2.1%   
Net working cap to sales %38.014.3 266.3%  
Current ratio x2.31.4 171.2%  
Inventory Days Days7658 131.0%  
Debtors Days Days2266 33.7%  
Net fixed assets Rs m8,098101,841 8.0%   
Share capital Rs m2300-   
"Free" reserves Rs m17,0880-   
Net worth Rs m17,3561,808,934 1.0%   
Long term debt Rs m0947,917 0.0%   
Total assets Rs m25,4003,315,181 0.8%  
Interest coverage x311.7-2.9 -10,856.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.3 370.7%   
Return on assets %11.8-2.3 -501.0%  
Return on equity %17.1-5.8 -297.4%  
Return on capital %26.9-3.0 -894.8%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,226143,216 2.3%  
From Investments Rs m-1,555-342,913 0.5%  
From Financial Activity Rs m-1,818192,667 -0.9%  
Net Cashflow Rs m-147-7,030 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: UNICHEM LAB  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  AJANTA PHARMA  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - IPCA LABS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS